Vectura Group Share Price (VEC)

136.13 +0.13 (+0.10%) delayed: 11:21AM BST
Bid price 135.75 Open price 135.25
Ask price 136.50 Prev close 136.00
High price 136.75 Spread 0.55%
Low price 134.25 Volume 1,113,337

Register now for FREE live Vectura Group share prices, Vectura Group stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Vectura Group Level 2 Data, indepth research tools and investor commentary for Vectura Group (VEC) and other London Stock Exchange equities.

Vectura Group Share Price Chart

Advanced Charts >>

Register now for FREE Vectura Group share price charts

Vectura Group Share Price Information

Name Vectura Group Epic VEC
Sector Pharmaceuticals & Biotechnology ISIN GB00B01D1K48
Activites Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura's main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25bn. Vectura has seven products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK). Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy. Index n/a

Vectura Group Key Numbers

Latest Share Price (p) 136.13 Net Gearing (%) -31.37
Market Capitalisation (£m) 544.05 Gross Gearing (%) 13.51
Shares in issue (m) 399.65 Debt Ratio 0.95
P/E Ratio -75.63 Debt-to-Equity Ratio 0.06
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.16
Dividend Yield (%) 0.00 Price to book value 4.03
Dividend cover (x) 0.00 ROCE -0.13
Earning per share (p) -1.80 EPS Growth (%) -38.46
52 week high / low 171.50 / 76.00 DPS Growth (%) n/a

Vectura Group Director Deals

Dec.Date Type Director Pos No. of Shares
13/03/2014 PLAC Dr Christopher Blackwell CEO 16,129
13/03/2014 PLAC Dr Trevor Phillips ED 6,452
13/03/2014 PLAC Paul Oliver FD 6,452
13/03/2014 PLAC Bruno Angelici NED 12,903
13/03/2014 PLAC Neil Warner NED 9,677

More Vectura Group Director Deals >>

Vectura Group Company News

16:52 17/04/2014

Holding(s) in Company

/* */ RNS Number : 1274F Vectura Group plc 17 April 2014      TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES   1. Identity of the issuer or the underlying issuer of existing shares to...

07:37 11/04/2014

Vectura to initiate Europe study for asthma drug Favolir

Vectura Group is to initiate a pivotal study in Europe later this calendar year for Favolir, its investigational product for severe, uncontrolled asthma. This decision underlines Vectura's planned strategy for a broad European development programme for Favolir, rather than a country-specific...

07:10 11/04/2014

FLASH: Vectura to initiate Europe study for asthma drug Favolir

Story provided by

More Vectura Group Company News >>

Register now for FREE Vectura Group company news

Vectura Group Share Price Discussions

13 days ago


Powered by IST's

Register now for FREE Vectura Group share price discussions